Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cyberonics Awaits Possible Takeover Bid; Stock Up Nearly 18% In March

This article was originally published in The Gray Sheet

Executive Summary

Cyberonics stock produced strong returns for investors in March as speculation about a possible takeover bid increased

You may also be interested in...



Expanded AngioSeal Supply Deal Heightens Investor Interest In Kensey Nash

Kensey Nash's ability to convince investors that AngioSeal will generate sales exceeding $75 mil. over the life of a multi-year contract with St. Jude Medical helped the supplier's stock price swell by more than 11% during June

Expanded AngioSeal Supply Deal Heightens Investor Interest In Kensey Nash

Kensey Nash's ability to convince investors that AngioSeal will generate sales exceeding $75 mil. over the life of a multi-year contract with St. Jude Medical helped the supplier's stock price swell by more than 11% during June

Ortho Firms Feel DoJ Probe Price As Stocks Fall In Q1; Will Zimmer Diversify?

The federal government's mounting scrutiny of orthopedic industry pricing practices for hip and knee replacement implants could convince Zimmer to more aggressively seek a presence in the artificial disc arena

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel